Lupin Receives FDA Approval for Hyperkalemia Treatment

The U.S. Food and Drug Administration (FDA) has approved Lupin's Sodium Zirconium Cyclosilicate for oral suspension, a drug designed to treat hyperkalemia (high potassium levels) in adults. The approval signifies that Lupin's drug is bioequivalent to AstraZeneca's Lokelma.